^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy
Excerpt:
...Patients ≥ 18 years of age with histologically, and radiographically confirmed non-metastatic ER-positive (defined as ≥30% of positive cells) and HER2-positive (defined as overexpression by immunohistochemistry (3+) or 2+ and positive by defined by fluorescence or dual in situ hybridization.) breast cancer with minimal tumor size over 2 cm (≥T2 lesion) to receive neoadjuvant chemotherapy recommended by the treating physician 2....
Trial ID:
Source:
Title:
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Excerpt:
...HER2 overexpression or amplification will be based on local test results and is defined as either: (i) IHC staining of 3+ (uniform, intense membrane staining) in greater than or equal to 10% of invasive tumor cells or, (ii) Fluorescent in situ hybridization (FISH) result of more than six HER2 gene copies per nucleus or, (iii) FISH ratio (HER2 gene signals to chromosome 17 signals) of greater than or equal to 2.0....
Trial ID:
More C2 evidence
Source:
Title:
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Excerpt:
...Includes patients with HER2 overexpression/activation as detected by PRO Onc Assay.`...
Trial ID:
Source:
Title:
A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging
Excerpt:
...Patients > 18 years of age with HER2-overexpressing early stage breast cancer (Stages I...
Trial ID:
Source:
Title:
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
Excerpt:
...- Overexpression and/or amplification of HER2 in an invasive component of the core biopsy, according to one of the following definitions: •>30% of invasive tumor cells showing strong complete circumferential membrane staining (score 3+) •HER2 gene amplification defined as >6 HER2 gene copies per nucleus by in situ hybridization....
Trial ID:
Source:
Title:
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
Excerpt:
...- Patients must be diagnosed with metastatic cytologically or histologically confirmed adenocarcinoma of the breast with HER2 over-expression or with newly diagnosed locally advanced (including inflammatory) breast cancer (LABC) with stage II-III disease; patients with metastatic (stage IV) disease (MBC) must have measurable lesions...
Trial ID:
Source:
Title:
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Excerpt:
...The magnitude of antibody levels will be assessed to the vaccine and HER-2 over-expressing cells (e.g.,BT474). ...
Trial ID:
Less C2 evidence
Source:
Title:
Predictors of pathologic complete response to neoadjuvant treatment in HER2-overexpressing breast cancer: a retrospective analysis using real-world data
Published date:
01/06/2022
Excerpt:
Ninety-four women with non-metastatic breast cancer and HER2 overexpression received neoadjuvant combination chemotherapy with Trastuzumab and Pertuzumab at FALP during the period 2017-2020. Seventy percent of patients achieved pCR, and in the group of hormone receptor negative patients, 89% of patients achieved pCR.
DOI:
10.3332/ecancer.2022.1338
Source:
Title:
228P - Pathologic response to neoadjuvant antiher2 therapy in HER2 equivocal overexpression with FISH amplification
Published date:
09/14/2020
Excerpt:
A serie of 71 early or locally advanced breast cancer patients with HER2 equivocal overexpression and FISH amplification who received neoadjuvant treatment with chemotherapy and antiHER2 drugs were analyzed their complete pathological response (pCR) and the clinical-pathological variables associated....Patients with equivocal HER2 overexpression and FISH amplification have an overall pCR of only 28.8%. More than 70% have ER positive, and the proportion of pCR is only 17.6%.
